CN111973704A - Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof - Google Patents
Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN111973704A CN111973704A CN202010802322.3A CN202010802322A CN111973704A CN 111973704 A CN111973704 A CN 111973704A CN 202010802322 A CN202010802322 A CN 202010802322A CN 111973704 A CN111973704 A CN 111973704A
- Authority
- CN
- China
- Prior art keywords
- parts
- chicory
- ampelopsis grossedentata
- composition
- wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000723343 Cichorium Species 0.000 title claims abstract description 54
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 241001018563 Nekemias grossedentata Species 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 36
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 16
- 240000000249 Morus alba Species 0.000 claims abstract description 13
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 13
- 241000234435 Lilium Species 0.000 claims abstract description 12
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 12
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 10
- 244000269722 Thea sinensis Species 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 39
- 239000008187 granular material Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010902 jet-milling Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 31
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 31
- 229940116269 uric acid Drugs 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 28
- 208000024891 symptom Diseases 0.000 abstract description 11
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 8
- 229930186217 Glycolipid Natural products 0.000 abstract description 8
- 208000006750 hematuria Diseases 0.000 abstract description 8
- 208000030159 metabolic disease Diseases 0.000 abstract description 8
- 206010030113 Oedema Diseases 0.000 abstract description 7
- 201000001474 proteinuria Diseases 0.000 abstract description 7
- 208000011580 syndromic disease Diseases 0.000 abstract description 7
- 230000004069 differentiation Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 239000004575 stone Substances 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 206010046337 Urate nephropathy Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 201000001431 Hyperuricemia Diseases 0.000 description 14
- 201000005569 Gout Diseases 0.000 description 12
- 230000003907 kidney function Effects 0.000 description 12
- 241001122767 Theaceae Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 240000007311 Commiphora myrrha Species 0.000 description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000018914 glucose metabolism disease Diseases 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a vine tea chicory composition and a preparation method and application thereof. The Ampelopsis grossedentata and chicory composition is prepared from Ampelopsis grossedentata leaves, chicory, cape jasmine, mulberry leaves, kudzu roots and lily. The composition takes medicinal and edible medicinal materials as raw materials, is reasonably proportioned according to the theory of traditional Chinese medicine, medicine properties and dosage, is in the best of pathogenesis, treats based on syndrome differentiation, and has obvious curative effect on dampness-heat blockage type uricemia (symptoms such as proteinuria, hematuria, edema, uric acid stone, glycolipid metabolic disorder and the like). In addition, the formula of the invention has no toxic or side effect, and is safe, reliable and convenient to take.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a vine tea chicory composition and a preparation method and application thereof.
Background
Hyperuricemia (HUA) is a metabolic disease mainly manifested by uric acid abnormality. With the change of the dietary structure of people, the incidence rate of Hyperuricemia (HUA) is increasing day by day, and because of the imbalance of uric acid metabolism of patients, uric acid in the body is difficult to be eliminated in time to form uric acid deposition, which leads to a series of complications. Uric acid deposits in joints to form gout; uric acid is deposited in the kidney unit, and a series of inflammatory reactions such as leucocyte phagocytosis and the like occur to cause kidney damage, so gout and gouty nephropathy are formed, and a series of manifestations such as proteinuria, hematuria, edema, uric acid calculi and the like are mainly clinically manifested. At present, gout and gouty nephropathy are main diseases affecting the health and daily life of people, patients need to suffer from long-term pain and need to take medicines regularly, the economic burden is heavy, and the cure difficulty of the disease is extremely high. For inflammatory reaction, western medicine mainly adopts non-steroidal anti-inflammatory drugs or glucocorticoids for treatment, and although symptoms of patients can be relieved, the side effect is large; at present, most of the medicines for treating hyperuricemia in western medicine, such as allopurinol and febuxostat, can obviously reduce uric acid by promoting uric acid excretion and inhibiting uric acid generation, but some patients have multiple side effects of gastrointestinal tract irritation, rash, liver damage and the like, and the use of the medicines is influenced. Meanwhile, both animal experiments and clinical researches show that hyperuricemia is closely related to islet beta cell injury, insulin resistance and diabetes, and certain relation exists among pathogenesis of hyperuricemia, hyperglycemia and hyperlipidemia. Therefore, the development of a medicine and food dual-purpose product which has better effects of preventing and reducing uric acid and can improve renal function and glycolipid metabolic disorder has important research value.
The traditional Chinese medicine does not have the disease names of hyperuricemia, gout and gouty nephropathy, but can belong to the categories of arthralgia syndrome, calendar festival and the like in the traditional Chinese medicine according to the clinical manifestations of the hyperuricemia, the gout and the gouty nephropathy, such as joint red swelling and hot pain; with uric acid kidney stone, hematuria and proteinuria as main manifestations, it can be classified into "urolithiasis", "hematuria" and "chylous stranguria".
From the perspective of traditional Chinese medicine, gouty nephropathy is classified into liver and kidney deficiency type, damp-heat arthralgia type and the like according to the etiology and pathogenesis of the gouty nephropathy, and most patients mostly have improper diet and are addicted to diet. The traditional Chinese medicine is fat, sweet and thick in taste, generates damp-heat in the interior of the body for a long time, affects the transportation and transformation functions of the spleen and the stomach, is unfavorable for ascending and descending qi activity, transports and transforms phlegm, drinks and dampness, fails to work, and turns into damp-toxin, dampness and turbidity flows down to the kidney mansion for a long time, and the damp-heat, phlegm and blood stasis and turbid-toxin blockage of the channels and collaterals and qi and blood stasis cause diseases, and belongs to the damp-heat blockage type according to the syndrome differentiation and classification. The ease of treatment and the means of treatment of different types of gouty nephropathy vary.
It is reported that about 40% of gout patients are accompanied by renal function abnormality, and hyperuricemia is also an independent risk factor of chronic renal damage, and the uric acid level is correlated with renal function progress; in addition, research suggests that hyperuricemia and dyslipidemia can increase the risk of diabetic microangiopathy. If the intervention is not performed in time, serious kidney failure such as uremia can be caused.
At present, there have been some reports of targeted studies on gout. For example, patent CN108159312A (published 20180615) discloses a composite plant active beverage capable of treating gout; patent CN108143907A (published japanese 20180612) discloses a health tea preparation; patent CN108403987A (published Japanese 20180817) discloses a chicory gardenia tea for preventing and treating gout; however, the formula mainly has the effect of treating gout, and the effect on damp-heat arthralgia type gouty nephropathy is not mentioned.
Therefore, the development of a medicine and food dual-purpose product which has better effects of preventing and reducing uric acid and can improve renal function and glycolipid metabolic disorder has important research value.
Disclosure of Invention
The invention aims to overcome the defect of the prior art that the traditional Chinese medicine formula for treating damp-heat arthralgia type gouty nephropathy is short, and provides a vine tea chicory composition. The ampelopsis grossedentata and chicory composition provided by the invention has an obvious effect on damp-heat arthralgia type gouty nephropathy (proteinuria, hematuria, edema, uric acid calculus and glycolipid metabolic disorder), and has the advantages of simple formula, no toxic or side effect, safety, reliability and convenience in taking.
The invention also aims to provide a preparation method of the vine tea and chicory composition.
The invention also aims to provide application of the vine tea and chicory composition in preparing a medicine or food for preventing or treating dampness-heat blockage type uricemia.
In order to achieve the purpose, the invention adopts the following technical scheme:
the ampelopsis grossedentata and chicory composition is characterized by comprising the following components in parts by mass:
5-12 parts of Ampelopsis grossedentata leaves,
2-8 parts of chicory,
1-5 parts of cape jasmine fruit,
0.5 to 5 parts of mulberry leaves,
0.5 to 3 parts of kudzu-vine root,
0.5-3 parts of lily.
The formula of the invention consists of Ampelopsis grossedentata leaves, chicory, cape jasmine, mulberry leaves, kudzu roots and lily, the Ampelopsis grossedentata leaves and the chicory are used as monarch drugs, the chicory has bitter taste, cold nature, heat-clearing and detoxifying, liver-clearing and gallbladder-benefiting, diuresis and detumescence, and is mainly used for treating damp-heat jaundice, nephritic edema, epigastric distending pain, inappetence and other symptoms, the Ampelopsis grossedentata leaves have bitter taste, slight astringent, cold nature, heat-clearing and diuresis-promoting, liver-calming and blood pressure lowering, inflammation-diminishing and diuresis, and is mainly used for treating diarrhea, stranguria with urine, hypertension, dizziness and other symptoms, and the combination of the two drugs can achieve the effects of heat-clearing, detoxifying, diuresis; the gardenia has the functions of clearing heat, promoting diuresis, cooling blood, removing toxicity, and the mulberry leaf has the functions of dispelling wind, clearing heat, cooling blood and improving eyesight; radix Puerariae has effects of invigorating yang, relieving muscles, promoting eruption, relieving diarrhea, relieving restlessness, relieving cough, and tranquilizing mind. The combination of the medicines can achieve the effects of clearing damp and discharging turbidity, clearing damp and heat, diminishing inflammation and promoting urination, can reduce uric acid, inhibit the generation of uric acid and promote the excretion of uric acid, can promote the balance of glycolipid metabolism, and has a protective effect on metabolic organs such as liver and kidney.
The composition takes medicinal and edible medicinal materials as raw materials, is reasonably proportioned according to the theory of traditional Chinese medicine, medicine properties and dosage, is disease-conscious, treats according to syndrome differentiation, and has obvious curative effect on dampness-heat blockage type uricemia (symptoms such as proteinuria, hematuria, edema, uric acid stones, glycolipid metabolic disorder and the like). In addition, the formula of the invention has no toxic or side effect, and is safe, reliable and convenient to take.
Preferably, the ampelopsis grossedentata chicory composition consists of the following components in parts by mass:
7-10 parts of Ampelopsis grossedentata leaves,
4-6 parts of chicory,
2-4 parts of gardenia, and the like,
1-3 parts of mulberry leaves,
0.5 to 2 parts of kudzu-vine root,
0.5-2 parts of lily.
More preferably, the ampelopsis grossedentata chicory composition is composed of the following components in parts by mass:
8 parts of Ampelopsis grossedentata leaves,
5 parts of chicory, namely 5 parts of,
3 parts of cape jasmine fruit, namely cape jasmine fruit,
2 parts of mulberry leaves, namely 2 parts of,
1 part of kudzu-vine root, radix puerariae,
1 part of lily.
Preferably, the ampelopsis grossedentata and chicory composition is a decoction, a wall-broken powder preparation or a wall-broken granule preparation or a preparation.
More preferably, the ampelopsis grossedentata and chicory composition is a wall-broken powder, and the particle size of the wall-broken powder is less than or equal to 75 microns.
More preferably, the ampelopsis grossedentata and chicory composition is a wall-broken granular preparation, and the particle size of the wall-broken granules is 20-60 meshes.
The invention also provides a preparation method of the wall-broken granular preparation, and all the components in the formula are used as medicines, so that the wall-broken granular preparation has better curative effect.
The preparation method of the ampelopsis grossedentata chicory composition comprises the following steps:
s1: coarsely pulverizing Ampelopsis grossedentata leaf, herba Cichorii, fructus Gardeniae, folium Mori, radix Puerariae and Bulbus Lilii respectively, mixing or coarsely pulverizing after mixing to obtain mixed fine powder; the particle size of the mixed fine powder is not less than 70 meshes;
s2: breaking the wall of the mixed fine powder and crushing the mixed fine powder until the particle size of the broken powder is not more than 75 mu m;
s3: and (5) performing wet granulation on the wall-broken powder obtained in the step (S2) to obtain the vine tea and chicory composition.
More preferably, the particle size of the mixed fine powder in S1 is 110 to 130 meshes.
Preferably, the wall-breaking crushing method of S2 is airflow wall-breaking crushing, and the crushing time is 20-40 min; the frequency of the step-by-step rotating speed positive rotation is 28.0-30.0 Hz.
Preferably, the wet granulation process in S3 is: mixing the wall-broken powder and the wetting agent, adding into a swing granulator for granulation, and drying to obtain the vine tea and chicory composition.
More preferably, the wetting agent is 60% ethanol.
More preferably, the mass ratio of the wall-broken powder to the wetting agent is 1: 0.55.
The application of the vine tea and chicory composition in preparing the medicine or food for preventing or treating the dampness-heat blockage type uricemia is also within the protection scope of the invention.
Compared with the prior art, the invention has the following beneficial effects:
the ampelopsis grossedentata and chicory composition provided by the invention has the advantages of simple formula, no toxic or side effect, safety, reliability and convenience in taking, has an obvious effect on damp-heat arthralgia type gouty nephropathy (proteinuria, hematuria, edema and uric acid stones), can promote the balance of glycolipid metabolism, and has a protection effect on metabolic organs such as liver and kidney.
Detailed Description
The invention is further illustrated by the following examples. These examples are intended to illustrate the invention and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples below, generally according to conditions conventional in the art or as suggested by the manufacturer; the raw materials, reagents and the like used are, unless otherwise specified, those commercially available from the conventional markets and the like. Any insubstantial changes and substitutions made by those skilled in the art based on the present invention are intended to be covered by the claims.
Examples 1 to 6
This example provides a series of ampelopsis grossedentata chicory compositions comprising the following components and amounts:
5-12 parts of Ampelopsis grossedentata leaves,
2-8 parts of chicory,
1-5 parts of cape jasmine fruit,
0.5 to 5 parts of mulberry leaves,
0.5 to 3 parts of kudzu-vine root,
0.5-3 parts of lily.
Specifically, the formulations and amounts of examples 1-6 are shown in Table 1.
TABLE 1 formulation of vine tea chicory compositions of examples 1 to 6 (parts/100 g)
| Formulation of | Ampelopsis grossedentata leaf | Chicory | Gardenia jasminoides ellis | Mulberry leaf | Kudzu root | Lily bulb |
| Example 1 | 8 | 5 | 3 | 2 | 1 | 1 |
| Example 2 | 5 | 2 | 1 | 0.5 | 0.5 | 0.5 |
| Example 3 | 12 | 8 | 5 | 5 | 3 | 3 |
| Example 4 | 7 | 4 | 2 | 1 | 0.5 | 0.5 |
| Example 5 | 10 | 6 | 4 | 3 | 2 | 2 |
| Example 6 | 9 | 5 | 3 | 2 | 1 | 1 |
。
The ampelopsis grossedentata chicory compositions of the examples were prepared into specific wall-broken granule formulations by the following method:
(1) coarse crushing: weighing Ampelopsis grossedentata leaves, chicory, gardenia, mulberry leaves, kudzu roots and lily according to the prescription amount, uniformly mixing, and crushing into 120-mesh mixed fine powder by a coarse crushing machine set.
(2) Breaking the wall and crushing: taking the mixed fine powder in the step (1), passing through a TC-40 type fluidized bed supersonic airflow grinding grading system, setting a grading rotation speed, rotating forward 28.0-30.0HZ, and grinding to obtain wall-broken powder of about 300 meshes.
(3) And (3) granulating: putting the wall breaking powder into a high-efficiency wet mixer, adding 60% ethanol as a wetting agent to prepare a soft material, wherein the adding amount of the fine powder and the 60% ethanol is about 1:0.55, granulating by using a swing granulator with a 24-mesh sieve pre-installed, putting the prepared wet granules into a hopper of a vertical boiling drying bed, setting the air inlet temperature of boiling drying to be 85 ℃ and the air outlet temperature to be 52 ℃, firstly opening the air inlet without opening the heating device for 5 minutes at the beginning so as to enable most of ethanol to escape, then opening the heating device, after the air outlet temperature exceeds 52 ℃, closing the heating device, and continuously introducing the air for about 10 minutes to obtain dry granules.
(4) Screening: and sieving the dry particles by a vibration sieving machine preloaded with an upper layer of 20 meshes and a lower layer of 60 meshes to obtain 20-60 meshes of vine tea and chicory composition particles. The granules of each example are marked as example 1-6-wall-broken granule preparation.
In addition, the formulation of example 1 was decocted to make a decoction (denoted as example 1-decoction) by the following procedure: according to the prescription of the example 1, according to the clinical traditional Chinese medicine decoction method, the traditional Chinese medicine is placed into a stainless steel pot, the stainless steel pot is spread, about 1000mL of water is added to the surface of myrrh 1-2 cm, the myrrh is soaked for 120min and decocted for 2 times, the decoction is poured out after 20min of boiling each time, the decoction is combined for 2 times, the decoction is decompressed and concentrated into extract containing 3g of crude drugs per milliliter, and the extract is stored at 4 ℃ for standby.
Meanwhile, the formula of example 1 is prepared into a wall-broken powder preparation (marked as example 1-wall-broken powder preparation) by a wall-breaking and crushing mode, and the process is as follows:
(1) coarse crushing: weighing Ampelopsis grossedentata leaves, chicory, gardenia, mulberry leaves, kudzu roots and lily according to the prescription amount, uniformly mixing, and crushing into 120-mesh mixed fine powder by a coarse crushing machine set.
(2) Breaking the wall and crushing: and (3) taking the mixed fine powder in the step (1), passing through a TC-40 type fluidized bed supersonic airflow crushing grading system, setting a grading rotation speed, rotating forwards at 28.0-30.0Hz, and crushing to obtain wall-breaking powder of about 300 meshes, wherein the wall-breaking powder is used as a wall-breaking powder preparation for later use.
Comparative example 1
This comparative example provides a Chinese medicinal composition of the formula in accordance with example 1 except that chicory is not included. The preparation process is also consistent with that of example 1, and the wall-broken granular preparation is prepared and recorded as a comparative example 1-group.
Comparative example 2
The present comparative example provides a Chinese medicinal composition, the formulation of which is identical to that of example 1, except that it does not contain Ampelopsis grossedentata leaves. The preparation process is also consistent with that of example 1, and the wall-broken granular preparation is prepared and recorded as a comparative example 2-group.
Comparative example 3
The present comparative example provides a Chinese medicinal composition, the formulation of which is identical to that of example 1, except that chicory is not included, and the amount of Ampelopsis grossedentata leaves is 13 parts. The preparation process is also consistent with that of example 1, and the wall-broken granular preparation is prepared and recorded as a comparative example 3-group.
Comparative example 4
The present comparative example provides a Chinese medicinal composition, the formulation of which is identical to that of example 1, except that the composition does not contain Ampelopsis grossedentata leaves, and the amount of chicory is 13 parts. The preparation process is also consistent with that of example 1, and the wall-broken granular preparation is prepared and recorded as a comparative example 4-group.
Performance testing
(1) Effect on hyperuricemia associated with renal injury model
1. Test article
Examples 1-6-wall-broken granule preparation, example 1-decoction, example 1-wall-broken powder preparation.
2. Laboratory animal
SPF grade male SD rats 60, body weight (220. + -. 10) g.
3. Experimental methods
Taking 84 SD rats, randomly taking 6 SD rats as blank control groups, and molding the rest 54 SD rats by a specific molding method: the stomach was perfused with 250 mg/(kg. d) oteracil potassium intraperitoneal injection combined yeast extract 3.5 mL/(kg. d) and adenine 50 mg/(kg. d), and the molding was continued for 5 weeks. After 5 weeks, 78 rats were randomly divided into 13 groups, namely a model group, an example 1-6 wall-breaking granule group, an example 1-decoction group, an example 1-wall-breaking powder preparation group and a comparative example 1-4 group, wherein each group was subjected to gavage administration of 4g (crude drug)/l 0g body weight according to the measurement, and a blank control group and the model group were subjected to normal saline with the same volume for 1 time a day for 21 days continuously.
4. Observation index
After 5 weeks of drug administration, blood was collected from orbital venous plexus of rats in each group, and the collected blood was placed at high speed3000 r.min in a low-temperature centrifuge-1Centrifuging for 10min, collecting supernatant, and measuring Serum Uric Acid (SUA), creatinine (SCR) and urea nitrogen (BUN) levels with full-automatic biochemical analyzer.
After 21 days of continuous administration, fasting is not forbidden for 24 hours, pentobarbital sodium (40 mg. kg-1) is adopted to perform intraperitoneal injection anesthesia according to 1.33 mL. kg-1, abdominal aorta is collected without anticoagulation, the abdominal aorta is placed in a high-speed low-temperature centrifuge, centrifugation is performed for 10min at 3000 r. min-1, supernatant is taken, and the levels of SUA, SCR and BUN in serum are measured by a full-automatic biochemical analyzer.
5. Statistical treatment
All data were analyzed using SPSS18.0 statistical software. Metering data
As shown, P <0.05 represents significant difference between groups by t-test.
6. Results
The test results are shown in Table 2.
TABLE 2 results of the Effect on hyperuricemia with renal injury model
Note: compared with the medicine before the administration, the medicine is prepared by the steps of,①P<0.05。
from the results, the potassium oxonate + adenine + yeast extract can be used for successfully carrying out the model of hyperuricemia and nephropathy complications on rats and merging the glucose metabolism disorder, after modeling, the SUA, Scr, BUN and fasting blood glucose of the model group are all obviously higher than those of a blank control group, and the Scr and BUN are marking indexes reflecting the renal function, which indicates that the serum uric acid level is obviously increased after modeling, the renal function is seriously damaged, the blood glucose is increased, and indicates that the glucose metabolism disorder is merged after modeling. After administration, the groups of the wall-broken granular preparation of examples 1 to 6, the group of the decoction of example 1 and the group of the wall-broken powder preparation of example 1 all have significantly reduced blood sugar, Scr, BUN and blood sugar before administration, and the differences have statistical significance (P <0.05), while the groups of the comparative examples 1 to 4 have significantly reduced blood sugar, Scr, BUN and blood sugar before administration (P <0.05), but have no statistical significance (P >0.05) compared with the differences before administration, which shows that the groups of the wall-broken granular preparation of examples 1 to 6, the group of the decoction of example 1 and the group of the wall-broken powder preparation of example 1 all reduce serum uric acid level of a rat model with gouty nephropathy, reduce serum Scr and BUN levels, improve renal function, reduce blood sugar level and improve sugar metabolism disorder. Meanwhile, the invention discovers that the aspects of reducing serum uric acid level and improving renal function of the wall-broken granule group in the embodiment 1 are obviously better than those of the decoction group in the embodiment 1 (P is less than 0.05), which shows that the wall-broken preparation group with full component administration has better effect. Example 1-the group of wall-broken particles and example 1-the group of wall-broken powder preparations had no statistical significance in comparison of differences in reducing serum uric acid levels, improving renal function and improving glycometabolism disorder (P >0.05), but the present inventors found that the group of wall-broken powder preparations of example 1 was easily hygroscopic and lumpy. Comparative examples 1-4, although they reduced serum uric acid levels, had no improvement in renal function and sugar metabolism disorders.
(2) Volunteer experiment
1. Experimental methods
According to the 'diagnosis, syndrome differentiation and type classification and curative effect evaluation of uric acid nephropathy', 40 patients with gout nephropathy and damp-heat arthralgia syndrome type according to syndrome differentiation of traditional Chinese medicine are selected; inclusion criteria were: firstly, the diagnosis standard of the gouty nephropathy in western medicine is met; secondly, the diagnosis standard of the damp-heat blockage type in the traditional Chinese medicine is met; and thirdly, the patients with the age of 30-70 years old. Exclusion criteria: (ii) secondary gout caused by other kidney diseases, blood diseases, tumor radiotherapy, chemotherapy or diuretics; ② kidney damage caused by hypertension, chronic nephromenelitis, etc.; ③ allopurinol anaphylaxis, obviously reduces leucocyte or blood platelet, and has serious liver function damage; patients in gestation or lactation period; people with allergic constitution or people allergic to various medicines in the recipe; sixthly, the relevant examination and the scoring cannot be matched. 40 volunteers were randomly divided into 20 cases each of the test group to which the wall-broken granule preparation of example 1 was administered (3 g/time, 3 times/day) and the control group. Allopurinol tablets (100 mg/time, 3 times/day) were given to the control group and the improvement of clinical symptoms and signs was observed in both groups. Serum creatinine (Scr), urea nitrogen (BUN), uric acid (SUA) and uroprotein and uremic occult blood before and after intervention.
2. Clinical symptom scoring scale
The improvement was evaluated according to the clinical symptom score scale of table 3.
TABLE 3 clinical symptom score Scale
3. Results of the experiment
Tables 4 to 6 show the results of the experiments.
TABLE 4 improvement of clinical symptoms before and after intervention
Note: compared with the control group, the compound of the formula,①P<0.05; compared to after intervention.
TABLE 5 comparison of serum uric acid and renal function indices before and after intervention
TABLE 6 Effect on urine protein and urine occult blood conditions before and after intervention
From the results, the wall-broken particle composition can be used for remarkably improving the clinical symptoms and physical signs of the damp-heat arthralgia type gouty nephropathy on the basis of the conventional western medicine treatment, the effect is superior to that of the conventional western medicine group, the serum uric acid level, the BUN and the Scr of a gouty nephropathy patient are remarkably improved after intervention, and the urine protein and the urine occult blood are also remarkably improved, so that the kidney function of the gouty nephropathy patient can be remarkably improved.
The ampelopsis grossedentata and chicory composition provided by the invention has the advantages of simple formula, no toxic or side effect, safety, reliability and convenience in taking, has a remarkable curative effect on dampness-heat blockage type uricemia (symptoms such as proteinuria, hematuria, edema and uric acid stones), can promote the balance of glycolipid metabolism, and has a protective effect on metabolic organs such as liver and kidney.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. The ampelopsis grossedentata and chicory composition is characterized by comprising the following components in parts by mass:
5-12 parts of Ampelopsis grossedentata leaves,
2-8 parts of chicory,
1-5 parts of cape jasmine fruit,
0.5 to 5 parts of mulberry leaves,
0.5 to 3 parts of kudzu-vine root,
0.5-3 parts of lily.
2. The ampelopsis grossedentata chicory composition according to claim 1, characterized by consisting of the following components in parts by mass:
7-10 parts of Ampelopsis grossedentata leaves,
4-6 parts of chicory,
2-4 parts of gardenia, and the like,
1-3 parts of mulberry leaves,
0.5 to 2 parts of kudzu-vine root,
0.5-2 parts of lily.
3. The ampelopsis grossedentata chicory composition according to claim 1, characterized by consisting of the following components in parts by mass:
8 parts of Ampelopsis grossedentata leaves,
5 parts of chicory, namely 5 parts of,
3 parts of cape jasmine fruit, namely cape jasmine fruit,
2 parts of mulberry leaves, namely 2 parts of,
1 part of kudzu-vine root, radix puerariae,
1 part of lily.
4. The Ampelopsis grossedentata chicory composition of claim 1 wherein said Ampelopsis grossedentata chicory composition is a decoction, a wall-broken powder formulation or a wall-broken granule formulation.
5. The Ampelopsis grossedentata chicory composition as claimed in claim 4, wherein said Ampelopsis grossedentata chicory composition is a wall-broken granule preparation, and the particle size of the granule is 20-60 mesh.
6. A process for the preparation of Ampelopsis grossedentata chicory compositions as claimed in any of claims 1 to 5, wherein,
s1: coarsely pulverizing Ampelopsis grossedentata leaf, herba Cichorii, fructus Gardeniae, folium Mori, radix Puerariae and Bulbus Lilii respectively, mixing or coarsely pulverizing after mixing to obtain mixed fine powder; the particle size of the mixed fine powder is not less than 70 meshes;
s2: breaking the wall of the mixed fine powder and crushing the mixed fine powder until the particle size of the broken powder is not more than 75 mu m;
s3: and (5) performing wet granulation on the wall-broken powder obtained in the step (S2) to obtain the ampelopsis grossedentata and chicory composition in a wall-broken granular preparation state.
7. The preparation method according to claim 6, wherein the S2 wall breaking and crushing method is jet milling, and the crushing time is 20-40 min; the frequency of the step-by-step rotating speed positive rotation is 28.0-30.0 Hz.
8. The method of claim 6, wherein the wet granulation process in S3 comprises: mixing the wall-broken powder and the wetting agent, adding into a swing granulator for granulation, and drying to obtain the vine tea and chicory composition.
9. The method of claim 8, wherein the wetting agent is 60% ethanol; the mass ratio of the wall-broken powder to the wetting agent is 1: 0.55.
10. Use of the Ampelopsis grossedentata chicory composition according to any of claims 1 to 5 for the preparation of a medicament or food for the prevention or treatment of wet-heat blockage type uricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010802322.3A CN111973704A (en) | 2020-08-11 | 2020-08-11 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010802322.3A CN111973704A (en) | 2020-08-11 | 2020-08-11 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111973704A true CN111973704A (en) | 2020-11-24 |
Family
ID=73434349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010802322.3A Pending CN111973704A (en) | 2020-08-11 | 2020-08-11 | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973704A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114794283A (en) * | 2022-06-02 | 2022-07-29 | 广州市致仁医药科技有限公司 | Efficient preparation method of health-care tea |
| CN114848745A (en) * | 2022-03-28 | 2022-08-05 | 山西振东五和医养堂股份有限公司 | Chicory and gardenia beverage and preparation method thereof |
| CN115252728A (en) * | 2022-09-06 | 2022-11-01 | 广州市致仁医药科技有限公司 | Heat-clearing, dampness-removing and lipid-lowering tea and preparation method thereof |
| CN115444893A (en) * | 2022-09-02 | 2022-12-09 | 陕西中药研究所(陕西医药信息中心) | Active substance composition for reducing uric acid and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825874A (en) * | 2015-05-07 | 2015-08-12 | 林艳芳 | Dai food capable of promoting uric acid metabolism and preparation method thereof |
| CN110448668A (en) * | 2019-08-27 | 2019-11-15 | 中山市中智药业集团有限公司 | A kind of Chinese medicine composition keeping gentle constitution, broken wall composition and preparation method thereof |
-
2020
- 2020-08-11 CN CN202010802322.3A patent/CN111973704A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825874A (en) * | 2015-05-07 | 2015-08-12 | 林艳芳 | Dai food capable of promoting uric acid metabolism and preparation method thereof |
| CN110448668A (en) * | 2019-08-27 | 2019-11-15 | 中山市中智药业集团有限公司 | A kind of Chinese medicine composition keeping gentle constitution, broken wall composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 余瀛鳌，采薇主编: "《这本书能让你摆脱痛风 长效降尿酸，除痛防复发》", 28 February 2019, 北京：中国轻工业出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848745A (en) * | 2022-03-28 | 2022-08-05 | 山西振东五和医养堂股份有限公司 | Chicory and gardenia beverage and preparation method thereof |
| CN114794283A (en) * | 2022-06-02 | 2022-07-29 | 广州市致仁医药科技有限公司 | Efficient preparation method of health-care tea |
| CN115444893A (en) * | 2022-09-02 | 2022-12-09 | 陕西中药研究所(陕西医药信息中心) | Active substance composition for reducing uric acid and application thereof |
| CN115444893B (en) * | 2022-09-02 | 2023-07-07 | 陕西中药研究所(陕西医药信息中心) | Uric acid reducing active substance composition and application thereof |
| CN115252728A (en) * | 2022-09-06 | 2022-11-01 | 广州市致仁医药科技有限公司 | Heat-clearing, dampness-removing and lipid-lowering tea and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111973704A (en) | Ampelopsis grossedentata and chicory composition as well as preparation method and application thereof | |
| CN104288501A (en) | Blood glucose reducing particle and preparation method thereof | |
| CN1947757B (en) | Leave of glutinous rehmannia extractive, its preparation method and use, medicines prepared with said extractives | |
| CN110833595B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN113318201A (en) | Health food for reducing uric acid and preparation method thereof | |
| CN109498771B (en) | Targeting composition for improving mild cognitive dysfunction and preparation method thereof | |
| CN101766777B (en) | Chinese medicine composite for treating chronic renal failure | |
| CN103223104A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method | |
| CN101966312B (en) | Chinese medicinal composition for treating chronic renal failure and preparation method thereof | |
| CN114404538B (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
| CN114177244B (en) | Traditional Chinese medicine composition for treating thyroid cancer and preparation method thereof | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN102018903B (en) | Pure traditional Chinese medicine preparation for treating glomerular diseases and preparation method thereof | |
| CN1267086C (en) | Medicine for treating diabetes and adjusting blood sugar concentration and its preparation | |
| CN101757527B (en) | Traditional Chinese medicine composition for treating nephritis and preparation method thereof | |
| CN111110825A (en) | Composition for reducing uric acid and preparation method and application thereof | |
| CN1062154C (en) | Method for producing Chinese patent medicine for curing diabetes and its pill | |
| CN107536938B (en) | Application of qi regulating and blood circulation promoting preparation in preparation of medicine for treating or preventing renal damage | |
| CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
| CN115068540B (en) | A Chinese medicinal composition for treating nephropathy, decoction and preparation method thereof, and a pill and preparation method thereof | |
| CN112717078B (en) | Traditional Chinese medicine composition, preparation thereof, preparation method and application | |
| CN114601891B (en) | Composition with anti-ulcerative colitis effect and preparation method thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN117244018B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |